143 related articles for article (PubMed ID: 36589400)
1. Evaluation of the efficacy of transdermal administration of maropitant in managing vomiting in cats.
Boukaache Y; Ferret ML; Khoukh VDK; Enache A; Iwaszkiw D; Bertin S; Bruno F
Open Vet J; 2022; 12(5):618-621. PubMed ID: 36589400
[TBL] [Abstract][Full Text] [Related]
2. Effects of maropitant in cats receiving dexmedetomidine and morphine.
Martin-Flores M; Sakai DM; Learn MM; Mastrocco A; Campoy L; Boesch JM; Gleed RD
J Am Vet Med Assoc; 2016 Jun; 248(11):1257-61. PubMed ID: 27172341
[TBL] [Abstract][Full Text] [Related]
3. Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs.
Hay Kraus BL
J Am Vet Med Assoc; 2014 Nov; 245(9):1015-20. PubMed ID: 25313812
[TBL] [Abstract][Full Text] [Related]
4. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats.
Hickman MA; Cox SR; Mahabir S; Miskell C; Lin J; Bunger A; McCall RB
J Vet Pharmacol Ther; 2008 Jun; 31(3):220-9. PubMed ID: 18471143
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Pentravan
Bourdon F; Lecoeur M; Leconte L; Ultré V; Kouach M; Odou P; Vaccher C; Foulon C
Int J Pharm; 2016 Dec; 515(1-2):774-787. PubMed ID: 27826027
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic effect of oral maropitant treatment before the administration of brimonidine ophthalmic solution in healthy cats.
Kanda T; Toda C; Morimoto H; Shimizu Y; Itoi T; Furumoto K; Okamura Y; Iwata E
J Feline Med Surg; 2020 Jun; 22(6):557-563. PubMed ID: 31313970
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of oral maropitant as an antiemetic in cats receiving morphine and dexmedetomidine.
Martin-Flores M; Sakai DM; Mastrocco A; Learn MM; Campoy L; Kirch PJ; Boesch JM; Gleed RD
J Feline Med Surg; 2016 Nov; 18(11):921-924. PubMed ID: 26534944
[TBL] [Abstract][Full Text] [Related]
9. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial.
Quimby JM; Brock WT; Moses K; Bolotin D; Patricelli K
J Feline Med Surg; 2015 Aug; 17(8):692-7. PubMed ID: 25336450
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of orally administered maropitant citrate in preventing vomiting associated with hydromorphone administration in dogs.
Hay Kraus BL
J Am Vet Med Assoc; 2014 May; 244(10):1164-9. PubMed ID: 24786163
[TBL] [Abstract][Full Text] [Related]
11. Effects of maropitant, acepromazine, and electroacupuncture on vomiting associated with administration of morphine in dogs.
Koh RB; Isaza N; Xie H; Cooke K; Robertson SA
J Am Vet Med Assoc; 2014 Apr; 244(7):820-9. PubMed ID: 24649993
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
Ramsey DS; Kincaid K; Watkins JA; Boucher JF; Conder GA; Eagleson JS; Clemence RG
J Vet Pharmacol Ther; 2008 Dec; 31(6):538-43. PubMed ID: 19000277
[TBL] [Abstract][Full Text] [Related]
13. Maropitant administered orally 2-2.5 h prior to morphine and dexmedetomidine reduces the incidence of emesis in cats.
Martin-Flores M; Mastrocco A; Lorenzutti AM; Campoy L; Kirch P; Stone M; Learn MM; Boesch JM
J Feline Med Surg; 2017 Aug; 19(8):876-879. PubMed ID: 27538868
[TBL] [Abstract][Full Text] [Related]
14. The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.
de la Puente-Redondo VA; Siedek EM; Benchaoui HA; Tilt N; Rowan TG; Clemence RG
J Small Anim Pract; 2007 Feb; 48(2):93-8. PubMed ID: 17286662
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone.
Hay Kraus BL
Vet Anaesth Analg; 2013 Jan; 40(1):28-34. PubMed ID: 23082784
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intramuscular maropitant in pigs (Sus scrofa domesticus).
Smith JS; Gebert JE; Ebner LS; Bennett KO; Collins RJ; Hampton CE; Kleine SA; Mulon PY; Smith CK; Seddighi R; Bussieres G; Mochel JP; Knych HK
J Vet Pharmacol Ther; 2023 May; 46(3):158-164. PubMed ID: 36872454
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs.
Rau SE; Barber LG; Burgess KE
J Vet Intern Med; 2010; 24(6):1452-7. PubMed ID: 21039869
[TBL] [Abstract][Full Text] [Related]
18. Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine.
Sharun K; Jambagi K; Arya M; Aakanksha ; Chaithra SN; Patel PK; Dixit SK; Dhama K
Arch Razi Inst; 2021 Nov; 76(5):1175-1182. PubMed ID: 35355772
[TBL] [Abstract][Full Text] [Related]
19. Dolasetron: a new option for nausea and vomiting.
Ogilvie GK
J Am Anim Hosp Assoc; 2000; 36(6):481-3. PubMed ID: 11105883
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of maropitant citrate after oral administration of multiple doses in adult horses.
Berryhill EH; Knych H; Chigerwe M; Edman J; Magdesian KG
J Vet Pharmacol Ther; 2020 May; 43(3):282-287. PubMed ID: 32067245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
